Welcome to our dedicated page for LBPS news (Ticker: LBPS), a resource for investors and traders seeking the latest updates and insights on LBPS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect LBPS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of LBPS's position in the market.
4D pharma plc (NASDAQ: LBPS) has successfully closed a senior secured credit facility with Oxford Finance LLC, allowing for up to $30 million in financing. The initial funding of $12.5 million extends the company's cash runway into Q4 2022, supporting their innovative Live Biotherapeutic programs. The financing consists of three tranches, with future funds contingent on achieving clinical milestones. The company aims to leverage this capital to further advance its unique microbiome-based therapeutic products, demonstrating significant progress in multiple clinical trials.
4D pharma plc (NASDAQ: LBPS) announces the passing of its Chief Financial Officer, John Beck, who had over 30 years of experience in the financial and biopharmaceutical industries. CEO Duncan Peyton expressed deep sorrow over Beck’s loss, highlighting his invaluable contributions to the company and the vision he had for its future. Despite this tragic event, 4D pharma's management team and Board of Directors will continue to lead the company, with succession planning in progress. 4D pharma specializes in developing Live Biotherapeutics, a new class of drugs derived from the microbiome.
4D pharma (NASDAQ: LBPS) has announced promising pre-clinical research on its immuno-oncology product MRx1299, which enhances CAR-T therapy effectiveness. Conducted in partnership with German institutions, the study published in Nature Communications highlights how the bacterium Megasphaera massiliensis and its metabolite pentanoate improve anti-tumor activity in animal models. This research supports 4D's ongoing clinical programs and showcases the potential of Live Biotherapeutics in cancer treatment.
4D pharma plc (NASDAQ: LBPS) announced that CEO Duncan Peyton and CSO Alex Stevenson will present at the Ladenburg Thalmann Healthcare Conference on July 13, 2021, at 2:30 PM ET. The presentation will include a corporate overview and a fireside chat. A webcast will be accessible in the 'Events' section of the company's website, with an archived replay available for 90 days. 4D pharma is a leader in developing Live Biotherapeutics, leveraging its proprietary MicroRx® platform to create single-strain bacterial therapies targeting various diseases, including cancer and asthma.
4D pharma plc (AIM: DDDD, NASDAQ: LBPS) announced that Development Director Christophe Carite will present the company's strategies for manufacturing Live Biotherapeutic products (LBPs) at the Microbiome Movement Drug Development Summit on July 1. The presentation will cover challenges in clinical-grade manufacturing, advancements in their cGMP facilities, and ongoing clinical trials, including four candidates progressing into trials in 2022. 4D pharma is recognized for its expertise in LBP development, with in-house facilities for scalable production and a strong pipeline targeting various unmet medical needs.
4D pharma plc (NASDAQ: LBPS) has completed enrollment of 30 patients in Part A of its Phase I/II clinical trial for MRx-4DP0004, targeting partly-controlled asthma. Results are expected in H2 2021. The company is discontinuing enrollment in its Phase II COVID-19 study in the UK to focus on asthma, citing increased vaccination rates and reduced hospitalizations. MRx-4DP0004 is an oral, immunomodulatory LBP that has shown promise in reducing airway inflammation. The trial's primary focus is safety, with secondary endpoints assessing lung function and quality of life.
4D pharma (NASDAQ: LBPS) announced positive data from its Phase II trial of LBP Blautix® for treating irritable bowel syndrome (IBS) with constipation (IBS-C) and diarrhea (IBS-D). The study revealed strong efficacy signals, particularly in the US, despite a high placebo response in UK and Ireland patients. Blautix, the first single-strain therapeutic for IBS-C and IBS-D, demonstrated significant improvements in bowel habits and abdominal pain. The company plans further regulatory discussions following these encouraging findings.
4D pharma plc (NASDAQ: LBPS) announced it will present data from its Phase II study of Blautix® for irritable bowel syndrome (IBS) subtypes IBS-C and IBS-D at Digestive Disease Week (DDW) 2021 from May 21-23. The presentation will occur on May 22, 2021, led by Dr. Eamonn Quigley. A virtual event will follow on May 25, 2021, analyzing the data and current IBS treatments, featuring a management presentation and Q&A session. 4D pharma specializes in Live Biotherapeutics and has multiple clinical programs underway, targeting various diseases.
4D pharma (NASDAQ: LBPS) has announced a collaboration with Parkinson’s UK to establish a Patient Advisory Board (PAB) comprising individuals living with Parkinson’s disease. This initiative aims to enhance patient-centric perspectives as 4D pharma advances its Live Biotherapeutic products for treating neurodegenerative conditions. The PAB will address patient issues related to current treatments and support 4D pharma's efforts in clinical engagement. This announcement builds on previous partnerships with the Michael J. Fox Foundation, emphasizing the urgent need for new treatments in a condition affecting 145,000 people in the UK.
4D pharma plc (NASDAQ: LBPS) reported its financial results for 2020, highlighting total equity of £28 million, a cash increase to £8.8 million, and a comprehensive loss of £25.9 million. The company advanced the Live Biotherapeutic MRx0518, demonstrating clinical efficacy in oncology trials. Significant milestones included completion of a merger with Longevity Acquisition Corporation and a NASDAQ listing. The company raised approximately £30 million through fundraising. The AGM is scheduled for 24 May 2021, with a virtual attendance format to comply with UK Government guidelines.
